{"id":381624,"date":"2020-11-16T08:03:36","date_gmt":"2020-11-16T13:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381624"},"modified":"2020-11-16T08:03:36","modified_gmt":"2020-11-16T13:03:36","slug":"abpro-announces-peer-reviewed-publication-demonstrating-efficacy-of-its-neutralizing-antibody-therapeutic-against-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abpro-announces-peer-reviewed-publication-demonstrating-efficacy-of-its-neutralizing-antibody-therapeutic-against-covid-19\/","title":{"rendered":"Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19"},"content":{"rendered":"
\n

\u25aa Data from the monkey challenge study published in Nature Communications showed a single dose of neutralizing antibody ABP 300 blocks infection of SARS-CoV-2 in prophylactic treatment and clears SARS-CoV-2 in three days in a therapeutic treatment setting<\/p>\n

\u25aa Safety demonstrated in non-human primates<\/p>\n

\u25aa ABP 300 showed the potential to neutralize eight SARS-CoV-2 strains with reported high-frequency mutations<\/p>\n

\u25aa Data support the continued evaluation of neutralizing antibody therapeutic, ABP 300, in human subjects<\/p>\n

WOBURN, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) — Abpro Corporation today announced the publication of a peer-reviewed article in the scientific journal Nature<\/em> Communications<\/em> titled, \u201cCharacterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.\u201d The publication is available online here<\/a>.<\/p>\n

ABP 300, referred to as MW05 in the publication, neutralizes COVID-19 by binding to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, blocking the viral interaction with the angiotensin-converting enzyme 2 (ACE2) receptors of host which are critical for viral entry and infection. Through this mechanism of action, ABP 300 not only completely and safely neutralizes COVID-19 in animal models but could potentially do so with superior safety and efficacy\u00a0than other monoclonal antibodies in development.<\/p>\n

\u201cWe are highly encouraged by this preclinical best-in-class proof-of-concept data showing the potential of our monoclonal antibodies to neutralize multiple SARS-CoV-2 strains. The data supports further development of antibody-based therapies for prophylactic and therapeutic treatment of COVID-19,\u201d said Ian Chan,\u00a0chief executive officer and co-founder\u00a0of\u00a0Abpro\u00a0Corporation. \u201cAs the SARS-CoV-2 mutates, which could undermine the effectiveness of vaccines and therapies, there is an urgent need for treatments that can address a broad range of strains.\u201d<\/p>\n

\n Study highlights:<\/strong>\n <\/p>\n